Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca Faces Setback From Lung Cancer Drug's Disappointing Trial Results
12:15pm, Tuesday, 10'th Sep 2024
A Phase 3 trial found AstraZeneca's (AZN) experimental lung cancer drug datopotamab deruxtecan (Dato-DXd) did not significantly improve patients' overall survival rates.
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
10:16am, Tuesday, 10'th Sep 2024
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nas
AstraZeneca Employees Detained in China: CEO Says Firm Is Working With Authorities
06:10am, Tuesday, 10'th Sep 2024
AstraZeneca CEO Pascal Soriot discusses China's detainment of five current and former employees for questioning about potential illegal activities. "We are working very closely with the authorities,"
AstraZeneca falls as cancer drug disappoints, analysts cuts FDA approval chances
05:56am, Tuesday, 10'th Sep 2024
Shares in AstraZeneca PLC (LSE:AZN) were the biggest drag on the FTSE 100 on Tuesday, falling over 4.5% on the back of some disappointing results from a trial of a lung cancer drug. Late-stage tria
AstraZeneca shares fall 5% on disappointing lung cancer drug trial results
04:43am, Tuesday, 10'th Sep 2024
AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.
AstraZeneca shares drop as lung cancer drug trial fails to improve survival
04:11am, Tuesday, 10'th Sep 2024
London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve overall survival resul
AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival
01:56pm, Monday, 09'th Sep 2024
Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in
3 Market-Beating Stocks to Buy for Less Than $100
05:15am, Friday, 06'th Sep 2024
AstraZeneca's robust pipeline and plentiful growth opportunities make it one of the best healthcare stocks to buy. Chewy is coming off a solid quarter, and there's still more growth ahead in the pet f
AstraZeneca Employees Held in China for Drug-Import, Data Privacy Investigations
03:52pm, Thursday, 05'th Sep 2024
Five current and former AstraZeneca (AZN) employees have been detained by police in China in connection with alleged violations of data privacy laws and for importing an unapproved cancer drug, accord
AstraZeneca slides after confirming five employees held by China police
11:09am, Thursday, 05'th Sep 2024
AstraZeneca PLC (LSE:AZN) shares fell 3.5% after it confirmed that five current and former employees in China are being held by police for questioning. The individuals, all Chinese nationals, worked
AstraZeneca says staff detained in China amid reports of a drug-import investigation
07:27am, Thursday, 05'th Sep 2024
Some employees of British pharmaceutical giant AstraZeneca have been detained by police in China as part of an investigation, the company confirmed Thursday. "We are aware a small number of our employ
AstraZeneca confirms five employees held by China police
05:17am, Thursday, 05'th Sep 2024
AstraZeneca PLC (LSE:AZN) has confirmed that five current and former employees in China are being held by police for questioning. The individuals, all Chinese nationals, worked in the company's oncolo
China detains AstraZeneca staff in data, drug-import probes, Bloomberg News reports
03:25am, Thursday, 05'th Sep 2024
The police in China have detained five current and former employees of AstraZeneca for questioning about potential illegal activities, Bloomberg News reported on Thursday, citing people familiar with
Nvidia whacked for $270bn as economic, AI concerns mount
03:52am, Wednesday, 04'th Sep 2024
Nvidia Corp's volatile nature was on full display when its share price fell nearly 10% before the closing bell on Tuesday. It meant a record $270 billion was stripped from the artificial intelligence
QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases
09:25am, Friday, 30'th Aug 2024
QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.
